Hebei Senlang Biotechnology Inc., Ltd. is developing SL1904B, an anti-CD19 CAR-T cell therapy targeting relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The market for CAR-T therapies is expanding, particularly in hematological malignancies, with increasing demand for effective treatments for relapsed or refractory cases. The competitive landscape includes established players like Novartis and Gilead, which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on regulatory pathways, potential partnerships, and reimbursement scenarios in the Chinese market, where the trial is currently recruiting patients.